Ayala Pharmaceuticals Inc (ADXS)

[mpreorder]

I really hope I'm wrong about this. But the PR seemed to me to indicate they killed the trial because the data didn't support continuing.
IF they ever publish (highly unlikely), or even make available (also highly unlikely), this data, we'll know for sure.

I'm aware of all they had planned for HER2. This is, after all, the construct pending approval in canine osteo.

I'm not above conspiracy-speculating, so how's this:
some tute or two were shorting themselves and needed a way out, so Advaxis cans DOC, then decides to kill a trial, opening the door for the tutes to drop the sp where they can cover cheaper. But the trial actually had indications of success and Advaxis is able to sell it, banking enough to avoid further dilution till axal gets approved in the EU.

I think this would only work if Lombardo likes both the color orange and flip-flops.